Novavax Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

8 brokers have issued 1-year price objectives for Novavax's stock. Their NVAX stock forecasts range from $35.00 to $209.00. On average, they predict Novavax's stock price to reach $164.00 in the next twelve months. This suggests a possible upside of 170.7% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

Novavax's stock was trading at $143.07 at the beginning of 2022. Since then, NVAX stock has decreased by 57.7% and is now trading at $60.59.
View the best growth stocks for 2022 here.

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported $2.56 EPS for the quarter, missing analysts' consensus estimates of $3.33 by $0.77. The biopharmaceutical company had revenue of $703.97 million for the quarter, compared to the consensus estimate of $845.20 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The firm's revenue for the quarter was up 57.4% on a year-over-year basis. During the same quarter last year, the company earned ($3.05) earnings per share.
View Novavax's earnings history.

Novavax shares reverse split on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

Novavax issued an update on its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NVAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $60.59.

Novavax (NASDAQ:NVAX) has a market capitalization of $4.73 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1,743,750,000.00 in net income (profit) each year or ($17.68) on an earnings per share basis.

Novavax employs 1,541 workers across the globe.

Novavax was founded in 1987.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for Novavax is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.